News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,711 Results
Type
Article (13945)
Company Profile (304)
Press Release (247462)
Section
Business (79356)
Career Advice (151)
Deals (13190)
Drug Delivery (34)
Drug Development (50328)
Employer Resources (31)
FDA (5682)
Job Trends (5116)
News (144134)
Policy (10018)
Tag
Academia (901)
Alliances (21525)
Alzheimer's disease (756)
Approvals (5661)
Artificial intelligence (68)
Bankruptcy (97)
Best Places to Work (4522)
Biotechnology (249)
Breast cancer (109)
Cancer (888)
Cardiovascular disease (71)
Career advice (132)
CAR-T (73)
Cell therapy (217)
Clinical research (40137)
Collaboration (308)
Compensation (128)
COVID-19 (1006)
C-suite (78)
Cystic fibrosis (66)
Data (983)
Diabetes (85)
Diagnostics (1207)
Drug discovery (56)
Earnings (29004)
Events (47193)
Executive appointments (247)
FDA (6047)
Funding (306)
Gene editing (63)
Gene therapy (163)
GLP-1 (310)
Government (1065)
Healthcare (6543)
Infectious disease (1043)
Inflammatory bowel disease (98)
IPO (7197)
Job creations (859)
Job search strategy (127)
Layoffs (188)
Legal (1375)
Lung cancer (130)
Lymphoma (62)
Manufacturing (86)
Medical device (2558)
Medtech (2559)
Mergers & acquisitions (6128)
Metabolic disorders (257)
Neuroscience (999)
NextGen Class of 2024 (2004)
Non-profit (847)
Northern California (1091)
Obesity (140)
Opinion (91)
Parkinson's disease (75)
Patents (61)
People (25103)
Phase I (14150)
Phase II (18664)
Phase III (11818)
Pipeline (367)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (201)
Real estate (1409)
Regulatory (8281)
Research institute (931)
Southern California (976)
Startups (1964)
United States (8655)
Vaccines (164)
Weight loss (83)
Date
Last 7 days (364)
Last 30 days (1399)
Last 365 days (20528)
2024 (20440)
2023 (22413)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16923)
Australia (2856)
California (2474)
Canada (809)
China (203)
Colorado (91)
Connecticut (103)
Europe (36445)
Florida (271)
Georgia (71)
Illinois (153)
Indiana (61)
Kansas (55)
Maryland (330)
Massachusetts (1955)
Minnesota (101)
New Jersey (630)
New York (682)
North Carolina (419)
Northern California (1091)
Ohio (82)
Pennsylvania (474)
South America (207)
Southern California (976)
Texas (278)
Washington State (247)
261,711 Results for "swanbio therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
SwanBio Evolves Leadership Team with Appointment of Executive Chair and Chief Operating Officer
SwanBio Therapeutics announced the addition of two industry veterans to the company’s leadership team: John Tsai, MD as executive chair, and Christopher “Topher” Brooke as chief operating officer.
October 16, 2023
·
3 min read
Drug Development
SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for Adrenomyeloneuropathy
SwanBio Therapeutics today announced it has begun the second dose-escalation cohort of its first interventional clinical study, PROPEL.
October 4, 2023
·
4 min read
Pharm Country
SwanBio Therapeutics Confirms Substantial Burden of Disease of Adrenomyeloneuropathy (AMN) in Both Men and Women
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, has conducted a healthcare resource use study confirming the substantial burden and economic impact of AMN on both men and women.
May 10, 2023
·
4 min read
Drug Development
SwanBio Therapeutics Initiates First-in-Human Study of AAV Gene Therapy for Adrenomyeloneuropathy
SwanBio Therapeutics today announced the initiation of its PROPEL clinical trial.
December 15, 2022
·
3 min read
Pharm Country
SwanBio Unveils Research in Next Generation CNS Capsids at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, presented preliminary data from primate studies of AAV capsids that outperform the commonly used AAV9 capsid.
May 18, 2023
·
4 min read
Drug Development
SwanBio Therapeutics to Present Preclinical Data on Lead Candidate at American Society of Gene & Cell Therapy
SwanBio Therapeutics to Present Preclinical Data on Lead Candidate at American Society of Gene & Cell Therapy 2022 Annual Meeting in Washington, DC May 16-19.
April 19, 2022
·
4 min read
Pharm Country
SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions
SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus -based therapies for the treatment of devastating, inherited neurological conditions, announced the completion of a $56 million Series B financing round, led by founding investors Syncona Limited and Mass General Brigham Ventures.
May 18, 2022
·
4 min read
Pharm Country
SwanBio Presents Design of Innovative Natural History Study Aimed to Evolve Understanding of Adrenomyeloneuropathy and Inform Future Treatments
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, today presented details about the company’s ongoing natural history study of adrenomyeloneuropathy (AMN) at the 8th Congress of the European Academy of Neurology (EAN) in Vienna.
June 27, 2022
·
4 min read
Pharm Country
SwanBio Therapeutics to Present New Preclinical Data Showcasing AAV-Based Gene Therapy Candidate for Adrenomyeloneuropathy at American Academy of Neurology Annual Meeting
SwanBio Therapeutics today announced that the company will present data supporting the clinical advancement of its lead candidate, SBT101, at the American Academy of Neurology (AAN) 2022 Annual Meeting.
March 4, 2022
·
3 min read
Drug Development
SwanBio Therapeutics Announces FDA Investigational New Drug Clearance for First AAV-Based Gene Therapy for the Treatment of Adrenomyeloneuropathy
SwanBio Therapeutics today announced that its Investigational New Drug (IND) application for its lead candidate, SBT101, for the treatment of adrenomyeloneuropathy (AMN) was cleared by the U.S. Food and Drug Administration (FDA).
January 25, 2022
·
3 min read
1 of 26,172
Next
